Birmingham, AL – 29 June 2011 – At Soluble Therapeutics, the Birmingham-based biotechnology company that provides solutions for proteins, working with The University of Alabama at Birmingham Biotechnology program students and faculty speaks to the company’s commitment to the biotechnology community and the continued progress of the Biotechnology program. It all starts with the students in the new Biotechnology Program at the University.
“Our company was founded on technology developed at the Center for Biophysical Sciences and Engineering on the UAB campus,” said Dr. Joseph N. Garner, CEO of Soluble Therapeutics. “We wanted to provide some of the students in UAB’s Biotechnology Program the chance to experience the biotechnology industry that they are training for and learning about first hand.”
Soluble Therapeutics currently hosts three student interns from the program’s first year and plans to continue to provide mentoring and an internship site for the Biotechnology program students. “It’s an incredible opportunity,” said Elizabeth Talley, one of the student interns. “Working with Dr. Garner and Soluble Therapeutics allows us to see how everything that we are learning in the Biotechnology program applies to directly to life in the biotechnology industry.” In the future, the company will apply for a grant that would allow for some of the master’s students to become paid employees of the company.
About the UAB Master’s in Biotechnology Program
The Biotechnology program was launched by The UAB School of Health Professions in August 2009. The program offers a biotechnology graduate certificate and/or a master’s degree. The current curriculum consists of three semesters of course work, a two-week internship at a biotechnology company, a research project and a scientific poster presentation at the end of the third semester.
The graduate-level program is designed to prepare a diverse student body for careers in various fields in biotechnology. The program prepares a student with foundational skills and knowledge they can translate to in a variety of job opportunities.
About Soluble Therapeutics
Soluble Therapeutics was founded in 2008 to commercialize the HSC™ Technology. The company’s products enhance the discovery process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics.
Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Operating out of Birmingham, Alabama, Soluble Therapeutics is the first to introduce protein formulation solutions that deliver the price/performance advantages of the HSCTM Technology. For additional information visit – www.soluble-Therapeutics.com.